| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 01/15/2014 | CN102701972B Octachlorostyrene hapten, artificial antigen and specific antibody |
| 01/15/2014 | CN102532283B Specific antibody of campylobacter jejuni specific multi-epitope artificial polypeptide and coated immunomagnetic beads and application thereof |
| 01/15/2014 | CN102099468B Anti-system ASC amino acid transporter 2 (ASCT2) antibody |
| 01/15/2014 | CN101985036B Amyloid- beta (1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use therof |
| 01/15/2014 | CN101809037B Human antibodies to human cd20 and method of using thereof |
| 01/15/2014 | CN101679520B Hutnfr1 selective antagonists |
| 01/14/2014 | US8629317 Non-human transgenic mammal for the constant region of the class a human immunoglobulin heavy chain and applications thereof |
| 01/14/2014 | US8629250 Hepcidin, hepcidin antagonists and methods of use |
| 01/14/2014 | US8629249 Streptococcus uberis adhesion molecule |
| 01/14/2014 | US8629248 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| 01/14/2014 | US8629247 Antibodies against prostate specific membrane antigen |
| 01/14/2014 | US8629245 Immunoglobulin Fc libraries |
| 01/14/2014 | US8629244 Interleukin-6 receptor binding polypeptides |
| 01/14/2014 | US8628777 Antibodies binding IL-1 related polypeptides |
| 01/14/2014 | US8628776 Human binding molecules against enterococci and Staphylococcus |
| 01/14/2014 | US8628775 Methods of reducing T cell-mediated immune responses with multimeric P-selectin and/or E-selectin compounds |
| 01/14/2014 | US8628773 Antigen binding proteins |
| 01/14/2014 | US8628772 Surface protein (HBsAg) variant of the hepatitis B virus |
| 01/14/2014 | US8628749 Radioimmunoconjugates and uses thereof |
| 01/14/2014 | CA2601368C Monoclonal and polyclonal antibodies to equine albumin and hemoglobin and apparatus and methods using the antibodies in the identification and localization of ulcers and other digestive tract bleeding in equines |
| 01/14/2014 | CA2561073C Composition and method for cancer treatment |
| 01/14/2014 | CA2445602C Nucleotide sequence for creatinine deiminase and method of use |
| 01/14/2014 | CA2426312C Compositions and methods for modulating rsv infection and immunity |
| 01/14/2014 | CA2402530C Blocking leukocyte emigration and inflammation by interfering with cd99 |
| 01/14/2014 | CA2370252C Cancer treatment with endothelin receptor antagonists |
| 01/09/2014 | WO2014008404A1 Antibodies to tau |
| 01/09/2014 | WO2014008218A1 Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
| 01/09/2014 | WO2014008054A2 Novel insecticidal proteins and methods for their use |
| 01/09/2014 | WO2014007513A1 Novel monoclonal antibody binding specifically to dll4 and use thereof |
| 01/09/2014 | WO2014007252A1 Protein marker, kit for diagnosis of occurrence of white root disease in hevea brasiliensis, and method for diagnosing occurrence of white root disease in hevea brasiliensis |
| 01/09/2014 | WO2014007198A1 Therapeutic agent for anemia including renal anemia and cancer-induced anemia which contains anti-bmp9 antibody as active ingredient |
| 01/09/2014 | WO2014006230A1 Il-20 epitopes and il-20 ligands |
| 01/09/2014 | WO2014006226A1 MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO |
| 01/09/2014 | WO2014006217A1 Dimeric protein with triple mutations |
| 01/09/2014 | WO2014006191A1 Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
| 01/09/2014 | WO2014006124A1 Covalently linked antigen-antibody conjugates |
| 01/09/2014 | WO2014006123A1 Anti-biotin antibodies and methods of use |
| 01/09/2014 | WO2014006118A1 Anti-theophylline antibodies and methods of use |
| 01/09/2014 | WO2014006105A1 Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
| 01/09/2014 | WO2014006100A1 Treatment for bone diseases |
| 01/09/2014 | WO2014005194A1 Immunological reagents and uses therefor |
| 01/09/2014 | WO2013173820A3 Bispecific scfv immunofusion (bif) |
| 01/09/2014 | WO2013166011A9 Binding proteins having tethered light chains |
| 01/09/2014 | WO2013163631A3 Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| 01/09/2014 | WO2013132452A3 Neisseria meningitidis compositions and methods thereof |
| 01/09/2014 | US20140013457 Methods of Modifying Eukaryotic Cells |
| 01/09/2014 | US20140013456 Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| 01/09/2014 | US20140011982 Antibodies Against Influenza Virus and Methods of Use Thereof |
| 01/09/2014 | US20140011981 Expression and secretion system |
| 01/09/2014 | US20140011811 Myosin binding protein-c for use in methods relating to diastolic heart failure |
| 01/09/2014 | US20140011731 Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof |
| 01/09/2014 | US20140011271 Notch1 receptor binding agents and methods of use thereof |
| 01/09/2014 | US20140011259 Protein Variants Having Modified Immunogenicity |
| 01/09/2014 | US20140011238 Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation |
| 01/09/2014 | US20140010864 Liposomes for protection against toxic compounds |
| 01/09/2014 | US20140010863 Liposomes for protection against toxic compounds |
| 01/09/2014 | US20140010849 Peanut allergy treatment |
| 01/09/2014 | US20140010829 Antibodies for tumor gangliosides |
| 01/09/2014 | US20140010825 Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
| 01/09/2014 | US20140010819 Method for correcting immunopathological reactions and a medicament |
| 01/09/2014 | US20140010818 Novel antibodies inhibiting c-met dimerization and uses thereof |
| 01/09/2014 | US20140010817 Novel Antibodies and Uses Thereof |
| 01/09/2014 | US20140010815 Monoclonal antibody having immunosuppressive activity or antigen binding fragment thereof |
| 01/09/2014 | US20140010814 Bi- and monospecific, asymmetric antibodies and methods of generating the same |
| 01/09/2014 | US20140010813 B-cell reduction using cd37-specific and cd20-specific binding molecules |
| 01/09/2014 | US20140010811 Antibodies to endoplasmin and their use |
| 01/09/2014 | US20140010810 Anti-Jagged 1/Jagged 2 Cross-Reactive Antibodies, Activatable Anti-Jagged Antibodies And Methods Of Use Thereof |
| 01/09/2014 | US20140010809 Binding domain-immunoglobulin fusion proteins |
| 01/09/2014 | US20140010808 Anti cd37 antibodies |
| 01/09/2014 | US20140010807 Novel compounds |
| 01/09/2014 | US20140010799 Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor |
| 01/09/2014 | US20140010798 Albumin fusion proteins |
| 01/09/2014 | US20140010759 Tumor specific anitbodies and uses therefor |
| 01/09/2014 | US20140007547 Method for inactivation/removal of coagulation factors by precipitation |
| 01/09/2014 | CA2878367A1 Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
| 01/09/2014 | CA2878263A1 Novel insecticidal proteins and methods for their use |
| 01/09/2014 | CA2877948A1 Paramyxovirus and methods of use |
| 01/09/2014 | CA2877746A1 Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
| 01/09/2014 | CA2877516A1 C-terminal and central epitope a-beta antibodies |
| 01/09/2014 | CA2877397A1 Antibodies to tau |
| 01/09/2014 | CA2876541A1 Mutant fragments of ospa and methods and uses relating thereto |
| 01/09/2014 | CA2876284A1 Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
| 01/08/2014 | EP2682475A1 Antibody and antigen recognizing tumor-initiating cells and use thereof |
| 01/08/2014 | EP2682405A1 Tumor necrosis factor- humanized antibody |
| 01/08/2014 | EP2682402A1 Ice crystallization inhibitor derived from plant seed |
| 01/08/2014 | EP2681245A1 Multivalent heteromultimer scaffold design and constructs |
| 01/08/2014 | EP2681244A1 Cea antibodies |
| 01/08/2014 | EP2681243A2 Anti-il-6 receptor antibodies and methods of use |
| 01/08/2014 | EP2681242A2 Sclerostin and dkk-1 bispecific binding agents |
| 01/08/2014 | EP2681241A1 Depleted anti-staphylococcal enterotoxins polyclonal antibodies, preparation and uses thereof |
| 01/08/2014 | EP2681240A1 Monovalent antigen binding proteins |
| 01/08/2014 | EP2681239A1 Antigen binding proteins |
| 01/08/2014 | EP2681237A1 Antagonistic dr3 ligands |
| 01/08/2014 | EP2680871A2 Parathyroid hormone analogs, compositions and uses thereof |
| 01/08/2014 | EP2468771A9 Pharmaceutical composition containing anti-hb-egf antibody as active ingredient |
| 01/08/2014 | CN103502438A Method and compositions for cellular immunotherapy |
| 01/08/2014 | CN103502274A Anti-il-6 receptor antibodies and methods of use |
| 01/08/2014 | CN103502273A Method and constructs for the pH dependent passage of the blood-brain-barrier |
| 01/08/2014 | CN103502272A Phosphated specific antibody for identifying Tau |
| 01/08/2014 | CN103502271A Antigen binding proteins |